Evidence map›Paper›PMID 22221328›Full record

ArticleCancer science2012

First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen.

Norihiko Takahashi, Takayuki Ohkuri, Shigenori Homma, Junya Ohtake, Daiko Wakita, Yuji Togashi, Hidemitsu Kitamura, Satoru Todo, Takashi Nishimura

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Colorectal cancer vaccines: Tumor-associated antigensWorld journal of gastroenterology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Norihiko TakahashiFirst Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan.
Takayuki Ohkuri
Shigenori Homma
Junya Ohtake
Daiko Wakita
Yuji Togashi
Hidemitsu Kitamura
Satoru Todo
Takashi Nishimura

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A patient with pulmonary metastasis of colon cancer was treated with artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP) of MAGE-A4 cancer antigen. The patient was vaccinated with MAGE-A4-H/K-HELP combined with OK432 and Montanide ISA-51. There were no severe side-effects except for a skin reaction at the injection site. MAGE-A4-H/K-HELP induced MAGE-A4-specific Th1 and Tc1 immune responses and the production of MAGE-A4-specific complement-fixing IgG antibodies. Tumor growth and carcinoembryonic antigen tumor marker were significantly decreased in the final diagnosis. This is the first report that artificially synthesized MAGE-A4-H/K-HELP induces Th1-dependent cellular and humoral immune responses in a human cancer patient.

Indexed as

Immunotherapy, ActiveAntigens, NeoplasmCancer VaccinesColonic NeoplasmsEpitopesHumansLung NeoplasmsMaleMiddle AgedNeoplasm ProteinsPrognosisTh1 CellsAntigens, NeoplasmCancer VaccinesEpitopesMAGEA4 protein, humanNeoplasm Proteins

Identifiers

PMID22221328
PMCPMC11164142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.